Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
Advances in diagnostics and novel therapies, including EB613 (EnteraBio), AGA2118 (Angitia Biopharmaceuticals), RT-102 (Rani Therapeutics), and others, are widening treatment options and boosting market value. LAS VEGAS Nov. 18, 2025 /PRNewswire/ -- DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, osteoporosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). DelveInsight Logo Osteoporosis Market Summary The market size for osteoporosis in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest osteoporosis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan. In the US, more than 53 million people either already have osteoporosis or are at high risk due
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rani Therapeutics to Participate in the Evercore Healthcare ConferenceGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewswire
- Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
RANI
Earnings
- 8/7/25 - Beat
RANI
Sec Filings
- 12/4/25 - Form EFFECT
- 12/3/25 - Form 424B5
- 11/25/25 - Form PRE
- RANI's page on the SEC website